WIRE — La mayor farmacéutica local apuesta por "bajar a menos de la mitad del precio en que actualmente se vende semaglutida". El obejtivo es competir con Novo Nordisk y Eli Lilly.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.